99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule

被引:0
作者
Torun Engfeldt
Thuy Tran
Anna Orlova
Charles Widström
Joachim Feldwisch
Lars Abrahmsen
Anders Wennborg
Amelie Eriksson Karlström
Vladimir Tolmachev
机构
[1] Royal Institute of Technology,School of Biotechnology
[2] Uppsala University,Unit of Biomedical Radiation Sciences, Rudbeck Laboratory
[3] Affibody AB,Section of Hospital Physics, Department of Oncology
[4] Uppsala University Hospital,undefined
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2007年 / 34卷
关键词
Affibody molecule; HER2; Peptide synthesis; Technetium-99m; Tumour targeting;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1843 / 1853
页数:10
相关论文
共 170 条
[1]  
Aunoble B(2000)Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review) Int J Oncol 16 567-576
[2]  
Sanches R(2004)HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review Br J Cancer 90 2344-2348
[3]  
Didier E(2005)Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases BJU Int 95 982-986
[4]  
Bignon YJ(2001)Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127-137
[5]  
Carlsson J(2001)2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 1865-1878
[6]  
Nordgren H(2005)Tumor markers in breast cancer—European Group on Tumor Markers recommendations Tumour Biol 26 281-923
[7]  
Sjostrom J(2001)Current use of HER2 tests Ann Oncol 12 S97-S100
[8]  
Wester K(2005)Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease Br J Cancer 93 552-556
[9]  
Villman K(2001)Trastuzumab and breast cancer N Engl J Med 345 995-996
[10]  
Bengtsson NO(2006)Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J Clin Oncol 24 2276-2282